GPR81 Ligand Identification via MD Simulations and Astrocyte cAMP
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying ligands for the GPR81 receptor, which is linked to cAMP signaling and involved in neuropathological conditions, are inefficient as they fail to recognize molecules with strong binding interactions, leading to ineffective treatment options for neurodevelopmental, neurodegenerative, and neurotraumatic disorders.
Innovation Solution
The use of molecular dynamics simulations to estimate binding energies of ligands to the GPR81 receptor, combined with cAMP measurements in living astrocytes, provides a robust method for identifying effective ligands that can modulate astrocytic metabolic responses, potentially treating diseases associated with abnormal astrocytic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ligand identification methods are used for GPR81 receptor, then the method is simple to operate, but it fails to recognize molecules with strong binding interactions, leading to low reliability in identifying effective ligands
Solution Approach 1:
The patent combines molecular dynamics simulations with cAMP measurement assays to create an integrated ligand identification method. This merging of computational and experimental approaches allows the system to detect binding interactions that conventional methods miss, thereby improving reliability without sacrificing excessive complexity
Solution Approach 2:
The patent introduces cAMP as an intermediary molecule to mediate the detection of ligand-receptor interactions. By measuring cAMP levels as a downstream effect of GPR81 activation, the method indirectly detects binding events with high reliability, overcoming the limitations of direct binding assays
2Reliability
If molecular dynamics simulations and cAMP measurements are used to identify ligands, then the reliability of ligand identification is improved, but the device complexity and time required increase
Solution Approach 1:
The patent performs molecular dynamics simulations as a preliminary screening step before conducting time-consuming cAMP measurements. This preliminary computational assessment filters out non-binding molecules, reducing the number of samples that require experimental validation and thereby minimizing overall screening time
Solution Approach 2:
The patent divides the ligand identification process into two distinct stages: computational screening via molecular dynamics simulations and experimental validation via cAMP measurements. This segmentation allows each stage to be optimized independently, with the computational stage handling high-throughput initial screening and the experimental stage providing detailed validation only for promising candidates
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reveals previously unrecognized potent actions of ligands on cAMP levels in astrocytes, offering a new method for selecting pharmacologic modulators that can effectively treat neuroinflammatory, neurodegenerative, and neurotraumatic conditions by elevating cAMP levels in astrocytes.
Implementation Method 1
determining whether said compound is a ligand for the GPR81 receptor by determining said compound's binding energy with the GPR81 receptor using molecular dynamics (MD) simulations
Implementation Method 2
cytosolic levels of cAMP ([cAMP]1) were measured by fluorescence nano-sensors in cultured astrocytes
Data Source
AI summary
The present invention pertains to a method for identifying a compound that can be used in mitigating and/or the treatment of a disease associated with abnormal astrocytic function, said method comprising: (i) providing a compound; (ii) determining whether said compound is a ligand for the GPR81 receptor by determining said compound's binding energy with the GPR81 receptor using molecular dynamics (MD) simulations and comparing said binding energy to the binding energy determined for a reference compound (such as L-lactate) with the GPR81 receptor; and (iii) if said compound is determined to be a ligand for the GPR81 receptor, bringing said compound in contact with a living astrocyte and determining the cAMP level in said astrocyte contacted with said compound. The present invention further pertains to an agent elevating the cAMP level in astrocytes for use in mitigating and/or in the treatment of a disease associated with abnormal astrocytic function.